Adil I Daud

Guest Editor for the following articles:

Jun
2018
Vol. 37. No. 2

Biomarkers for immune therapy in melanoma

Douglas B. Johnson, MD | Jeewon Chon, BS | Mark R. Johnson, BS | Justin M. Balko, PharmD, PhD
Over the past 5 to 10 years, a completely new class of immune therapies, termed immune checkpoint inhibitors, has been introduced. Monoclonal antibodies targeting programmed death-1 (PD-1) and cytotoxic T lymphocyte antigen-4 (CTLA-4) have now utterly changed the prognosis of patients with high risk and metastatic melanoma as well as other cancers.
MORE
Jun
2018
Vol. 37. No. 2

Immunotherapy for melanoma

Lauren M. Cuevas, MS | Adil Daud, MD
By augmenting preexisting antitumor immunity and preventing tumors from co-opting immune checkpoints, immunotherapy allows the immune system to destroy cancer cells.
MORE